Stock CYCN CYCLERION THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Cyclerion Therapeutics, Inc.

Equities

CYCN

US23255M2044

Market Closed - Nasdaq
Other stock markets
 21:30:00 10/05/2024 BST 		5-day change 1st Jan Change
3.15 USD +5.00% Intraday chart for Cyclerion Therapeutics, Inc. +6.60% -5.97%
05-07 Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-05 Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cyclerion Appoints Regina Graul, Ph.D., as President
AQ
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
AQ
Cyclerion Therapeutics, Inc. - Tisento Launches with $81 Million from Top-Tier Investor Syndicate and Promising Cyclerion Assets
AQ
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
AQ
CYCLERION THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
AQ
Cyclerion Therapeutics : Private Placement - Form 8-K
PU
CYCLERION THERAPEUTICS, INC. : Unregistered Sale of Equity Securities, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
AQ
Cyclerion Announces Reverse Stock Split
GL
CYCLERION THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sale of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
GL
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018
GL
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018
AQ
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
AQ
CYCLERION THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement
GL
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement
GL
Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases
GL
Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases
AQ
CYCLERION THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CYCN Stock
  4. News Cyclerion Therapeutics, Inc.
  5. Press Releases